Aesica to lead £200,000 project to improve manufacturing of API

Aesica leading consortium to improve sustainability of an API

Aesica has secured a Technology Strategy Board grant to fund a high-value chemical manufacturing process with the winning process set to improve the sustainability of an active pharmaceutical Ingredient (API).

CDMO Aesica won the grant as part of a consortium, which also comprises Charnwood Technical Consulting, CatScl and Biocatalysts.   The grant aims to help companies to trial new processes and to create demonstration scale prototypes.

“One of the key goals of the project is to improve upon the current manufacturing process of an API (Active Pharmaceutical Ingredient) through process innovation. That is, the goal is to improve efficiency, reduce waste, improve quality and development a more environmentally sustainable process,” Barrie Rhodes, Director of Technology Development at Aesica, told in-Pharmatechnologist.com. 

In principle the technology could be licensed by other manufacturers, he added. “A more likely benefit of this work will be the creation of know-how within the consortium that individual consortium members could exploit in other areas outside the scope of this project with Aesica.”

The company declined to provide information about the industrial biotechnology route to be investigated as part of the project, or the API involved. The project, valued at £200,000 ($336,000), is scheduled to finish in 2014. 

The grant aims to encourage collaboration between the chemical sector and industrial biotechnology developers, marrying biological and chemical practices.

Biocatalyst will use “Design for Manufacture” principles to discover, develop and manufacture novel enzymes to generate APIs.  CatScl will assess the feasibility of a value-adding novel industrial biotechnology route to an API. Charnwood Technical Consulting’s contribution is to assist in the design and scale-up of the process, as well as give expert guidance on quality and regulatory issues. 

“A successful project would create a highly efficient, second-generation API process that is less harmful to the environment. Other benefits would be the generation of a process that is more cost-effective and has fewer manufacturing steps,” Rhodes told us.  

In a statement, the company said: “Aesica will manage the overall project and carry out scale-up studies to determine the feasibility of the technology at larger scale. Utilising biocatalytic processes in the production of high value chemicals is environmentally friendly and forms part of an initiative to assist the chemicals industry in the shift away from dependency on fossil fuels towards a bio-economy based on renewable and biological compounds.”

Related News

Outsourcing up for GMP APIs as Onyx completes manufacturing deal

Outsourcing up for GMP APIs as Onyx completes manufacturing deal

(Picture credit: Jean-Pierre/Flickr)

100 year-old rules on API impurities to change in 2015

Aesica adds roller compaction unit in growing German market

Aesica adds roller compaction unit in growing German market

Aesica HQ in Newcastle, UK

Consort Medical cites growing Bespak as driver for £230m Aesica acquisition

Aesica fined £100,000 after worker critically injured

Aesica fined after bromine leak injured worker at API plant

Aesica and EmulTech team on microencapsulation

Aesica and EmulTech Claim Micro-Encapsulation can Revive Formulation Projects

Aesica opens new plant for oral diabetes drug

Aesica opens new plant for oral diabetes drug

Aesica lauds Britest collaboration benefits

Collaboration With Britest Already Paying Off Says Aesica

Aesica predicts more CMO consolidation and hints at acqusitions

Aesica predicts more CMO consolidation and hints at acquisitions

Aesica Licenses Stealthy Anti-Abuse Tech

Aesica Adds Stealthy Anti-Abuse Tech to Controlled Drug Offering

New Tech Director: Aesica Offers One-Stop Shop Manufacturing

New Tech Director: Aesica Offers One-Stop Shop Manufacturing

Related Products

See more related products